454 related articles for article (PubMed ID: 12745750)
21. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
22. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
23. Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients?
Sommerburg O; Grune T; Hampl H; Riedel E; Ehrich JH; Siems WG
Clin Nephrol; 2000 Feb; 53(1 Suppl):S23-9. PubMed ID: 10746802
[TBL] [Abstract][Full Text] [Related]
24. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
[TBL] [Abstract][Full Text] [Related]
25. Plasma concentrations of vitamin C, vitamin E and/or malondialdehyde as markers of oxygen free radical production during hemodialysis.
Hultqvist M; Hegbrant J; Nilsson-Thorell C; Lindholm T; Nilsson P; Lindén T; Hultqvist-Bengtsson U
Clin Nephrol; 1997 Jan; 47(1):37-46. PubMed ID: 9021240
[TBL] [Abstract][Full Text] [Related]
26. Oxidative stress, sister chromatid exchanges and apoptosis in the pathogenesis of lymphocytopenia in ESRD patients.
Pernice F; Floccari F; Nostro L; Caccamo C; Belghity N; Mantuano S; Romeo A; Barilla' A; Aloisi C; Ruello A; Frisina N; Buemi M
J Nephrol; 2006; 19(5):613-20. PubMed ID: 17136690
[TBL] [Abstract][Full Text] [Related]
27. Effects of intravenous iron on mononuclear cells during the haemodialysis session.
Martin-Malo A; Merino A; Carracedo J; Alvarez-Lara MA; Ojeda R; Soriano S; Crespo R; Ramirez R; Aljama P
Nephrol Dial Transplant; 2012 Jun; 27(6):2465-71. PubMed ID: 22207322
[TBL] [Abstract][Full Text] [Related]
28. The effect of serum albumin level on iron-induced oxidative stress in chronic renal failure patients.
Sezer MT; Akin H; Demir M; Erturk J; Aydin ZD; Savik E; Tunc N
J Nephrol; 2007; 20(2):196-203. PubMed ID: 17514624
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory, degenerative and vascular lesions in long-term dialysed patients.
Vrabie CD; Petrescu A; Waller M; Cojocaru M; Ciocâlteu A; Dina I
Rom J Intern Med; 2009; 47(2):149-59. PubMed ID: 20067165
[TBL] [Abstract][Full Text] [Related]
30. Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels.
Michelis R; Sela S; Kristal B
Nephrol Dial Transplant; 2005 Sep; 20(9):1963-9. PubMed ID: 15956071
[TBL] [Abstract][Full Text] [Related]
31. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study.
Anraku M; Kitamura K; Shintomo R; Takeuchi K; Ikeda H; Nagano J; Ko T; Mera K; Tomita K; Otagiri M
Clin Biochem; 2008 Oct; 41(14-15):1168-74. PubMed ID: 18692036
[TBL] [Abstract][Full Text] [Related]
32. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
[TBL] [Abstract][Full Text] [Related]
33. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
[TBL] [Abstract][Full Text] [Related]
35. Glucose-added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis.
Burmeister JE; Scapini A; da Rosa Miltersteiner D; da Costa MG; Campos BM
Nephrol Dial Transplant; 2007 Apr; 22(4):1184-9. PubMed ID: 17272314
[TBL] [Abstract][Full Text] [Related]
36. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
37. The influence of the hemodialysis treatment time under oxidative stress biomarkers in chronic renal failure patients.
Valentini J; Grotto D; Paniz C; Roehrs M; Burg G; Garcia SC
Biomed Pharmacother; 2008; 62(6):378-82. PubMed ID: 18166291
[TBL] [Abstract][Full Text] [Related]
38. Oxidative stress markers and C-reactive protein in pediatric patients on hemodialysis.
Elshamaa MF; Sabry S; Nabih M; Elghoroury EA; El-Saaid GS; Ismail AA
Ann Nutr Metab; 2009; 55(4):309-16. PubMed ID: 19828941
[TBL] [Abstract][Full Text] [Related]
39. Oxidative stress in hemodialysis--postdialytic changes.
Dakshinamurty KV; Rao PV; Saibaba KS; Sheela RB; Sreekrishna V; Venakataramana G; Shyam C; Jayaseelan L
Clin Lab; 2003; 49(5-6):255-61. PubMed ID: 15285183
[TBL] [Abstract][Full Text] [Related]
40. Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients.
De Vecchi AF; Bamonti F; Novembrino C; Ippolito S; Guerra L; Lonati S; Salini S; Aman CS; Scurati-Manzoni E; Cighetti G
Nephrol Dial Transplant; 2009 Aug; 24(8):2524-9. PubMed ID: 19264746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
